Mucosal administration of anti-bacterial antibody (Ab) provides long-term cross-protection against Pseudomonas aeruginosa respiratory infection
A. Pitiot (Tours, France), M. Ferreira (Tours, France), C. Parent (Tours, France), C. Boisseau (Tours, France), M. Cortes (Tours, France), L. Bouvart (Tours, France), N. Aubrey (Tours, France), C. Paget (Tours, France), N. Heuzé-Vourc'H (Tours, France), T. Secher (Tours, France)
Source: International Congress 2022 – Basic science of respiratory infection
Session: Basic science of respiratory infection
Session type: Thematic Poster
Number: 1817
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Pitiot (Tours, France), M. Ferreira (Tours, France), C. Parent (Tours, France), C. Boisseau (Tours, France), M. Cortes (Tours, France), L. Bouvart (Tours, France), N. Aubrey (Tours, France), C. Paget (Tours, France), N. Heuzé-Vourc'H (Tours, France), T. Secher (Tours, France). Mucosal administration of anti-bacterial antibody (Ab) provides long-term cross-protection against Pseudomonas aeruginosa respiratory infection. 1817
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|